Weekly shot aims to tame dangerous fat levels in the blood

NCT ID NCT07693777

Not yet recruiting Disease control Sponsor: Zhejiang Doer Biologics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This Phase 3 trial tests an investigational biologic called DR10624, given as a weekly injection, in adults with severe hypertriglyceridemia (very high blood fats) who are already on standard lipid-lowering therapy. The study compares two doses of DR10624 against a placebo to see if it can safely lower triglyceride levels and reduce related risks like pancreatitis. About 480 participants will receive weekly injections for 64 weeks, with the main goal of measuring the drop in fasting triglycerides at 26 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DR10624 (a biologic injection)
What this could lead to: If successful, this could provide a new weekly injection option to sharply lower severe high triglycerides and reduce the risk of pancreatitis.
What could go wrong: This is an early Phase 3 trial, so results may not confirm benefit or safety. Side effects from the injection or immune reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTRIGLYCERIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia hypertriglyceridemia metabolic dysfunction-associated steatotic liver disease pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTRIGLYCERIDEMIA SEVERE HYPERTRIGLYCERIDEMIA (SHTG)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Zhongshan Hospital

Shanghai, China

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.